Given the adverse prognosis associated with FLT3-ITD mutations in patients treated with IC, European LeukemiaNet (ELN) 2017 guidelines classified AML as favorable-, intermediate-, or adverse-risk dependent upon co-mutations in NPM1, and the FLT3-ITD allelic ratio (AR: mutated alleles/wild-type alleles) [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.